
The FDA approves durvalumab for bladder cancer and gefurulimab for myasthenia gravis, creating distinct ADC, biologic, and autoinjector production needs.
Click the title above to open the Pharmaceutical Technology July 2019 issue in an interactive PDF format.
over 7 years ago
Playbooks Are Not Just Child’s Playover 7 years ago
New Line of Rotary Valvesover 7 years ago
Planetary Dual Dispersers and Advanced Discharge Systemsover 7 years ago
Updated Pump Headover 7 years ago
FDA Revamps Biosimilar Quality Requirementsover 7 years ago
Plate Reader Offers Real-Time Detection and Analysisover 7 years ago
Automating Quality Checksover 7 years ago
Considerations for Sterile Filtration of Biologic Drugsover 7 years ago
Gene Therapies Propel Outsourcing Investment





